Mohd Z, Ahmad S, Yaacob N, Mohd Shariff N, Jaeb M, Hussin Z
Healthcare (Basel). 2023; 11(13).
PMID: 37444763
PMC: 10341500.
DOI: 10.3390/healthcare11131929.
Djochie R, Anto B, Opare-Addo M
J Pharm Policy Pract. 2023; 16(1):70.
PMID: 37291618
PMC: 10249546.
DOI: 10.1186/s40545-023-00577-6.
Desai S, Mondal D, Bera S
Sci Rep. 2021; 11(1):8331.
PMID: 33859215
PMC: 8050055.
DOI: 10.1038/s41598-021-86767-1.
Holzman S, Atre S, Sahasrabudhe T, Ambike S, Jagtap D, Sayyad Y
JMIR Form Res. 2019; 3(3):e13411.
PMID: 31456581
PMC: 6734854.
DOI: 10.2196/13411.
Madeira de Oliveira S, Altmayer S, Zanon M, Sidney-Filho L, Moreira A, Dalcin P
PLoS One. 2018; 13(9):e0202593.
PMID: 30204763
PMC: 6133354.
DOI: 10.1371/journal.pone.0202593.
Levamisole as an Adjuvant to Short-Course Therapy in Newly Diagnosed Pulmonary Tuberculosis Patients.
Shamkuwar C, Meshram S, Mahakalkar S
Adv Biomed Res. 2017; 6:37.
PMID: 28516071
PMC: 5385702.
DOI: 10.4103/2277-9175.203162.
The impact of social conditions on patient adherence to pulmonary tuberculosis treatment.
Choi H, Chung H, Muntaner C, Lee M, Kim Y, Barry C
Int J Tuberc Lung Dis. 2016; 20(7):948-54.
PMID: 27287649
PMC: 6013067.
DOI: 10.5588/ijtld.15.0759.
Reply to "compliance with antimicrobial therapy for buruli ulcer".
Phillips R, Sarfo F, Abass M, Frimpong M, Ampadu E, Forson M
Antimicrob Agents Chemother. 2014; 58(10):6341.
PMID: 25225343
PMC: 4187934.
DOI: 10.1128/AAC.03874-14.
Non-adherence of new pulmonary tuberculosis patients to anti-tuberculosis treatment.
Kulkarni P, Akarte S, Mankeshwar R, Bhawalkar J, Banerjee A, Kulkarni A
Ann Med Health Sci Res. 2013; 3(1):67-74.
PMID: 23634333
PMC: 3634227.
DOI: 10.4103/2141-9248.109507.
The value of effective public tuberculosis treatment: an analysis of opportunity costs associated with multidrug resistant tuberculosis in Latvia.
Miller T, Cirule A, Wilson F, Holtz T, Riekstina V, Cain K
Cost Eff Resour Alloc. 2013; 11(1):9.
PMID: 23594422
PMC: 3637239.
DOI: 10.1186/1478-7547-11-9.
Patient education and counselling for promoting adherence to treatment for tuberculosis.
Mimunya J, Kredo T, Volmink J
Cochrane Database Syst Rev. 2012; (5):CD006591.
PMID: 22592714
PMC: 6532681.
DOI: 10.1002/14651858.CD006591.pub2.
Treatment adherence among sputum smear-positive pulmonary tuberculosis patients in mountainous areas in China.
Yao S, Huang W, van den Hof S, Yang S, Wang X, Chen W
BMC Health Serv Res. 2011; 11:341.
PMID: 22176718
PMC: 3261108.
DOI: 10.1186/1472-6963-11-341.
Noncompliance to DOTS: How it can be Decreased.
Mittal C, Gupta S
Indian J Community Med. 2011; 36(1):27-30.
PMID: 21687377
PMC: 3104704.
DOI: 10.4103/0970-0218.80789.
Does directly observed therapy (DOT) reduce drug resistant tuberculosis?.
Moonan P, Quitugua T, Pogoda J, Woo G, Drewyer G, Sahbazian B
BMC Public Health. 2011; 11:19.
PMID: 21214913
PMC: 3032680.
DOI: 10.1186/1471-2458-11-19.
Multi-level barriers to LTBI treatment: a research note.
Hill L, Blumberg E, Sipan C, Schmitz K, West J, Kelley N
J Immigr Minor Health. 2008; 12(4):544-50.
PMID: 19085104
PMC: 2904450.
DOI: 10.1007/s10903-008-9216-5.
Chest diseases-important advances in clinical medicine: current treatment of pulmonary tuberculosis.
Slutkin G
West J Med. 1984; 140(1):85-6.
PMID: 18749489
PMC: 1011047.
Barriers and enablers in the management of tuberculosis treatment in Addis Ababa, Ethiopia: a qualitative study.
Sagbakken M, Frich J, Bjune G
BMC Public Health. 2008; 8:11.
PMID: 18186946
PMC: 2257959.
DOI: 10.1186/1471-2458-8-11.
[Factors related to non-compliance with active tuberculosis treatment in Montreal 1992-1995].
Cator M, Brassard P, Ducic S, Culman K
Can J Public Health. 2002; 93(2):92-7.
PMID: 11963527
PMC: 6979829.
Drug-resistant tuberculosis in a tertiary referral teaching hospital of Korea.
Lee J, Chang J
Korean J Intern Med. 2002; 16(3):173-9.
PMID: 11769576
PMC: 4531726.
DOI: 10.3904/kjim.2001.16.3.173.
Tuberculosis: 9. Treatment.
Hershfield E
CMAJ. 1999; 161(4):405-11.
PMID: 10478167
PMC: 1230544.
